Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives

키워드

참고문헌 (253)

1. Mackowiak B, "Alcohol-associated liver disease", J Clin Invest, 134, pp.e176345~ (2024)
2. Parola M, "Liver fibrosis in NAFLD", NASH : from pathophysiology towards diagnostic and therapeutic strategies, 2024, pp.95, 101231~
3. Singal AK, "Emerging targets for therapy in ALD : Lessons from NASH", Hepatology, 80, pp.223~237 (2024)
4. Ajmera V, "A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes", J Hepatol, 78, pp.471~478 (2023)
5. Rong L, "Advancements in the treatment of non-alcoholic fatty liver disease(NAFLD)", Front Endocrinol(Lausanne), 13, pp.1087260~ (2023)
6. Wang R, "Gut microbiome, liver immunology, and liver diseases", Cell Mol Immunol, 18, pp.4~17 (2021)
7. Albillos A, "The gut-liver axis in liver disease : Pathophysiological basis for therapy", J Hepatol, 72, pp.558~577 (2020)
8. Tilg H, "Non-alcoholic fatty liver disease : the interplay between metabolism, microbes and immunity", Nat Metab, 3, pp.1596~1607 (2021)
9. Moayedfard Z, "The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles", Stem Cell Res Ther, 13, pp.242~ (2022)
10. Gao B, "Inflammatory pathways in alcoholic steatohepatitis", J Hepatol, 70, pp.249~259 (2019)
11. Sutti S, "Adaptive immunity : an emerging player in the progression of NAFLD", Nat Rev Gastroenterol Hepatol, 17, pp.81~92 (2020)
12. Tilg H, "Gut-liver axis : Pathophysiological concepts and clinical implications", Cell Metab, 34, pp.1700~1718 (2022)
13. Bauer KC, "Nonalcoholic fatty liver disease and the gut-liver axis : Exploring an undernutrition perspective", Gastroenterology, 162, pp.1858~1875 (2022)
14. Park SH, "Ethanol and its nonoxidative metabolites promote acute liver injury by inducing ER stress, adipocyte death, and lipolysis", Cell Mol Gastroenterol Hepatol, 15, pp.281~306 (2023)
15. Scheja L, "Metabolic interplay between white, beige, brown adipocytes and the liver", J Hepatol, 64, pp.1176~1186 (2016)
16. Nati M, "The role of innate immune cells in nonalcoholic fatty liver disease", J Innate Immun, 14, pp.31~41 (2022)
17. Gramignoli R, "Effects of pro-inflammatory cytokines on hepatic metabolism in primary human hepatocytes", Int J Mol Sci, 23, pp.14880~ (2022)
18. Seitz HK, "Alcoholic liver disease", Nat Rev Dis Primers, 4, pp.16~ (2018)
19. Avila MA, "Recent advances in alcohol-related liver disease(ALD) : summary of a Gut round table meeting", Gut, 69, pp.764~780 (2020)
20. Gao B, "Alcoholic liver disease : pathogenesis and new therapeutic targets", Gastroenterology, 141, pp.1572~1585 (2011)
21. Mandrekar P, "Immunity and inflammatory signaling in alcoholic liver disease", Hepatol Int, 8(Suppl 2), pp.439~446 (2014)
22. Szabo G, "Gut-liver axis in alcoholic liver disease", Gastroenterology, 148, pp.30~36 (2015)
23. Shim YR, "Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease", Exp Mol Med, 52, pp.772~780 (2020)
24. Miyata T, "Programmed cell death in alcohol-associated liver disease", Clin Mol Hepatol, 26, pp.618~625 (2020)
25. Zafari N, "Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease : Molecular mechanisms, biomarkers, and therapeutic prospective", Life Sci, 305, pp.120760~ (2022)
26. Malaguarnera G, "Gut microbiota in alcoholic liver disease : pathogenetic role and therapeutic perspectives", World J Gastroenterol, 20, pp.16639~16648 (2014)
27. Huang W, "The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD", Biomed Pharmacother, 135, pp.111235~ (2021)
28. Gyongyosi B, "Alcohol-induced IL-17A production in Paneth cells amplifies endoplasmic reticulum stress, apoptosis, and inflammasome-IL-18 activation in the proximal small intestine in mice", Mucosal Immunol, 12, pp.930~944 (2019)
29. Liu H, "Compound probiotic ameliorates acute alcoholic liver disease in mice by modulating gut microbiota and maintaining intestinal barrier", Probiotics Antimicrob Proteins, 15, pp.185~201 (2023)
30. Hosseinkhani F, "The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases", Gut Microbes, 13, pp.1~22 (2021)
31. Hammerich L, "Hepatic inflammatory responses in liver fibrosis", Nat Rev Gastroenterol Hepatol, 20, pp.633~646 (2023)
32. Pal A, "Beneficial effects of eicosapentaenoic acid on the metabolic profile of obese female mice entails upregulation of HEPEs and increased abundance of enteric Akkermansia muciniphila", Biochim Biophys Acta Mol Cell Biol Lipids, 1867, pp.159059~ (2022)
33. Parker R, "Alcohol, adipose tissue and liver disease : mechanistic links and clinical considerations", Nat Rev Gastroenterol Hepatol, 15, pp.50~59 (2018)
34. Joshi-Barve S, "Alcoholic, nonalcoholic, and toxicant-associated steatohepatitis : Mechanistic similarities and differences", Cell Mol Gastroenterol Hepatol, 1, pp.356~367 (2015)
35. Haghgoo SM, "Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease : a systematic review", Clin Chem Lab Med, 57, pp.577~610 (2019)
36. Mathur M, "Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding", Hepatology, 77, pp.1688~1701 (2023)
37. Keshavarzian A, "Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats", J Hepatol, 50, pp.538~547 (2009)
38. Voican CS, "Alcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease", Liver Int, 35, pp.967~978 (2015)
39. Fantuzzi G, "Adipose tissue, adipokines, and inflammation", J Allergy Clin Immunol, 115, pp.911~919 (2005)
40. Li W, "Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis : A prospective observational study", Hepatology, 66, pp.575~590 (2017)
41. Hyun J, "Pathophysiological aspects of alcohol metabolism in the liver", Int J Mol Sci, 22, pp.5717~ (2021)
42. Kim JE, "The roles and associated mechanisms of adipokines in development of metabolic syndrome", Molecules, 27, pp.334~ (2022)
43. Correale J, "Multiple sclerosis and obesity : The role of adipokines", Front Immunol, 13, pp.1038393~ (2022)
44. Shen H, "Brown fat activation mitigates alcohol-induced liver steatosis and injury in mice", J Clin Invest, 129, pp.2305~2317 (2019)
45. van Beek SMM, "Prolonged β2-adrenergic agonist treatment improves glucose homeostasis in diet-induced obese UCP1-", -mice, 2021, pp.320, E619~E628
46. Crombie IK, "Modifying Alcohol Consumption to Reduce Obesity(MACRO) : development and feasibility trial of a complex community-based intervention for men", Health Technol Assess, 21, pp.1~150 (2017)
47. Lumeng CN, "Obesity induces a phenotypic switch in adipose tissue macrophage polarization", J Clin Invest, 117, pp.175~184 (2007)
48. Zhou Y, "Roles of necroptosis in alcoholic liver disease and hepatic pathogenesis", Cell Prolif, 55, pp.e13193~ (2022)
49. Kaczmarek A, "Necroptosis : the release of damage-associated molecular patterns and its physiological relevance", Immunity, 38, pp.209~223 (2013)
50. Hao L, "ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis", Gut, 70, pp.1933~1945 (2021)
51. King AL, "Involvement of the mitochondrial permeability transition pore in chronic ethanol-mediated liver injury in mice", Am J Physiol Gastrointest Liver Physiol, 306, pp.G265~G277 (2014)
52. McDaniel K, "The functional role of microRNAs in alcoholic liver injury", J Cell Mol Med, 18, pp.197~207 (2014)
53. Frank D, "Pyroptosis versus necroptosis : similarities, differences, and crosstalk", Cell Death Differ, 26, pp.99~114 (2019)
54. Kondylis V, "RIP Kinases in liver cell death, inflammation and cancer", Trends Mol Med, 25, pp.47~63 (2019)
55. Yuan J, "Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases", Nat Rev Neurosci, 20, pp.19~33 (2019)
56. Shi J, "Pyroptosis : Gasdermin-mediated programmed necrotic cell death", Trends Biochem Sci, 42, pp.245~254 (2017)
57. Coll RC, "NLRP3 and pyroptosis blockers for treating inflammatory diseases", Trends Pharmacol Sci, 43, pp.653~668 (2022)
58. Arioz BI, "Melatonin attenuates LPS-induced acute depressive-like behaviors and microglial NLRP3 inflammasome activation through the SIRT1", Nrf2 Pathway, 2019, pp.10, 1511~
59. Yao H, "Gut microbiota regulates chronic ethanol exposure-induced depressive-like behavior through hippocampal NLRP3-mediated neuroinflammation", Mol Psychiatry, 28, pp.919~930 (2023)
60. Zhong W, "Paneth cell dysfunction mediates alcohol-related steatohepatitis through promoting bacterial translocation in mice : Role of zinc deficiency", Hepatology, 71, pp.1575~1591 (2020)
61. Chen X, "Trimetazidine affects pyroptosis by targeting GSDMD in myocardial ischemia", reperfusion injury, 2022, pp.71, 227~241
62. Li LX, "Iron overload in alcoholic liver disease : underlying mechanisms, detrimental effects, and potential therapeutic targets", Cell Mol Life Sci, 79, pp.201~ (2022)
63. Ferrao K, "Iron and iron-related proteins in alcohol consumers : cellular and clinical aspects", J Mol Med(Berl), 100, pp.1673~1689 (2022)
64. Wang L, "ATF3 promotes erastin-induced ferroptosis by suppressing system Xc", Cell Death Differ, 27, pp.662~675 (2020)
65. Ali N, "Liver iron loading in alcohol-associated liver disease", Am J Pathol, 193, pp.1427~1439 (2023)
66. Hu CL, "Reduced expression of the ferroptosis inhibitor glutathione peroxidase-4 in multiple sclerosis and experimental autoimmune encephalomyelitis", J Neurochem, 148, pp.426~439 (2019)
67. Jia M, "Ferroptosis as a new therapeutic opportunity for nonviral liver disease", Eur J Pharmacol, 908, pp.174319~ (2021)
68. Targher G, "MASLD : a systemic metabolic disorder with cardiovascular and malignant complications", Gut, 73, pp.691~702 (2024)
69. European Association for the Study of the Liver(EASL), "EASL-EASDEASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)", J Hepatol, 81, pp.492~542 (2024)
70. Aron-Wisnewsky J, "Gut microbiota and human NAFLD : disentangling microbial signatures from metabolic disorders", Nat Rev Gastroenterol Hepatol, 17, pp.279~297 (2020)
71. Azzu V, "adipose tissue-liver cross talk in the control of whole-body metabolism : Implications in nonalcoholic fatty liver disease", Gastroenterology, 158, pp.1899~1912 (2020)
72. Zhang X, "Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites", Gut, 70, pp.761~774 (2021)
73. Aron-Wisnewsky J, "Nonalcoholic fatty liver disease : Modulating gut microbiota to improve severity?", Gastroenterology, 158, pp.1881~1898 (2020)
74. Mohamad Nor MH, "The effect of probiotics(MCP® BCMC®Strains)on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with nonalcoholic fatty liver disease", Nutrients, 13, pp.3192~ (2021)
75. Schoeler M, "Dietary lipids, gut microbiota and lipid metabolism", Rev Endocr Metab Disord, 20, pp.461~472 (2019)
76. Jiao N, "Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD", Gut, 67, pp.1881~1891 (2018)
77. Ji Y, "Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease(NAFLD)", Nutrients, 11, pp.1712~ (2019)
78. Jin M, "Regulation of toll-like receptor(TLR)signaling pathways in atherosclerosis : from mechanisms to targeted therapeutics", Acta Pharmacol Sin, 44, pp.2358~2375 (2023)
79. Ochando J, "Trained immunity-basic concepts and contributions to immunopathology", Nat Rev Nephrol, 19, pp.23~37 (2023)
80. Wang S, "Natural Killer-like B cells prime innate lymphocytes against microbial infection", Immunity, 45, pp.131~144 (2016)
81. He Y, "Immunopathobiology and therapeutic targets related to cytokines in liver diseases", Cell Mol Immunol, 18, pp.18~37 (2021)
82. Koenen M, "Obesity, adipose tissue and vascular dysfunction", Circ Res, 128, pp.951~968 (2021)
83. Rajesh Y, "Association of adipose tissue and adipokines with development of obesity-induced liver cancer", Int J Mol Sci, 22, pp.2163~ (2021)
84. Saponaro C, "Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals", Liver Int, 42, pp.2418~2427 (2022)
85. Adachi M, "High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase", Hepatology, 47, pp.677~685 (2008)
86. Chatterjee S, "Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis", J Hepatol, 58, pp.778~784 (2013)
87. Marra F, "Lipotoxicity and the gut-liver axis in NASH pathogenesis", J Hepatol, 68, pp.280~295 (2018)
88. Mouton AJ, "Obesity, hypertension, and cardiac dysfunction : Novel roles of immunometabolism in macrophage activation and inflammation", Circ Res, 126, pp.789~806 (2020)
89. Ni Y, "Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin", Endocrinology, 156, pp.987~999 (2015)
90. Zhao B, "S100A9 blockade prevents lipopolysaccharide-induced lung injury via suppressing the NLRP3 pathway", Respir Res, 22, pp.45~ (2021)
91. Pruenster M, "S100A8", A9 : From basic science to clinical application, 2016, pp.167, 120~131
92. Cao Y, "Kupffer cells play a crucial role in monocrotaline-induced liver injury by producing TNF-α", Toxicology, 468, pp.153101~ (2022)
93. Choe SS, "Adipose tissue remodeling : Its role in energy metabolism and metabolic disorders", Front Endocrinol(Lausanne), 7, pp.30~ (2016)
94. Kim SJ, "Adipocyte death preferentially induces liver injury and inflammation through the activation of chemokine(C-C Motif)receptor 2-positive macrophages and lipolysis", Hepatology, 69, pp.1965~1982 (2019)
95. Shojaie L, "Cell death in liver diseases : A review", Int J Mol Sci, 21, pp.9682~ (2020)
96. Brenner C, "Decoding cell death signals in liver inflammation", J Hepatol, 59, pp.583~594 (2013)
97. Schwabe RF, "Apoptosis and necroptosis in the liver : a matter of life and death", Nat Rev Gastroenterol Hepatol, 15, pp.738~752 (2018)
98. Bernardi S, "TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse", Clin Sci(Lond), 132, pp.69~83 (2018)
99. Xu X, "Targeted therapeutics and novel signaling pathways in nonalcohol-associated fatty liver", steatohepatitis(NAFL, Signal Transduct Target Ther, pp.2022, 7[DOI]
100. Cho YS, "Phosphorylation-driven assembly of the RIP1-RIP3complex regulates programmed necrosis and virus-induced inflammation", Cell, 137, pp.1112~1123 (2009)
101. Luedde T, "Cell death and cell death responses in liver disease : mechanisms and clinical relevance", Gastroenterology, 147, pp.765~783 (2014)
102. Roychowdhury S, "Receptor interacting protein 3protects mice from high-fat diet-induced liver injury", Hepatology, 64, pp.1518~1533 (2016)
103. Yu P, "Pyroptosis : mechanisms and diseases", Signal Transduct Target Ther, 6, pp.128~ (2021)
104. Arend WP, "IL-1, IL-18, and IL-33 families of cytokines", Immunol Rev, 223, pp.20~38 (2008)
105. Filali-Mouncef Y, "The ménage à trois of autophagy, lipid droplets and liver disease", Autophagy, 18, pp.50~72 (2022)
106. Senft D, "UPR, autophagy, and mitochondria crosstalk underlies the ER stress response", Trends Biochem Sci, 40, pp.141~148 (2015)
107. Lyamzaev KG, "Induction of autophagy by depolarization of mitochondria", Autophagy, 14, pp.921~924 (2018)
108. Mridha AR, "NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice", J Hepatol, 66, pp.1037~1046 (2017)
109. Racanelli V, "The liver as an immunological organ", Hepatology, 43(2 Suppl 1), pp.S54~S62 (2006)
110. Cheng ML, "The immune niche of the liver", Clin Sci(Lond), 135, pp.2445~2466 (2021)
111. Pikarsky E, "Focal and local : Ectopic lymphoid structures and aggregates of myeloid and other immune cells in liver", Gastroenterology, 151, pp.780~783 (2016)
112. Saviano A, "Single-cell genomics and spatial transcriptomics : Discovery of novel cell states and cellular interactions in liver physiology and disease biology", J Hepatol, 73, pp.1219~1230 (2020)
113. Kalucka J, "Single-cell transcriptome atlas of murine endothelial cells", Cell, 180, pp.764~779 (2020)
114. Zheng C, "Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing", Cell, 169, pp.1342~1356 (2017)
115. Zhao J, "Single-cell RNA sequencing reveals the heterogeneity of liver-resident immune cells in human", Cell Discov, 6, pp.22~ (2020)
116. Bogdanos DP, "Liver immunology", Compr Physiol, 3, pp.567~598 (2013)
117. Botía-Sánchez M, "B Cells and microbiota in autoimmunity", Int J Mol Sci, 22, pp.4846~ (2021)
118. Gaudin E, "Bcell homeostasis, competition, resources, and positive selection by self-antigens", Immunol Rev, 197, pp.102~115 (2004)
119. Catalán D, "Immunosuppressive mechanisms of regulatory B cells", Front Immunol, 12, pp.611795~ (2021)
120. Cargill T, "The role of B cells and B cell therapies in immune-mediated liver diseases", Front Immunol, 12, pp.661196~ (2021)
121. Barrow F, "Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling", Hepatology, 74, pp.704~722 (2021)
122. Bruzzì S, "B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease(NAFLD)", Free Radic Biol Med, 124, pp.249~259 (2018)
123. Khan S, "Emerging concepts in intestinal immune control of obesity-related metabolic disease", Nat Commun, 12, pp.2598~ (2021)
124. Courey-Ghaouzi AD, "Alternative B cell differentiation during infection and inflammation", Front Immunol, 13, pp.908034~ (2022)
125. Sanz I, "Challenges and opportunities for consistent classification of human B cell and plasma cell populations", Front Immunol, 10, pp.2458~ (2019)
126. Kanemitsu-Okada K, "Role of B cell-activating factor in fibrosis progression in a murine model of non-alcoholic steatohepatitis", Int J Mol Sci, 24, pp.2509~ (2023)
127. Miyake T, "B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease", Hepatol Int, 7, pp.539~547 (2013)
128. Nutt SL, "The generation of antibody-secreting plasma cells", Nat Rev Immunol, 15, pp.160~171 (2015)
129. Moro-Sibilot L, "Mouse and human liver contain immunoglobulin A-secreting cells originating from Peyer’s patches and directed against intestinal antigens", Gastroenterology, 151, pp.311~323 (2016)
130. Kotsiliti E, "Intestinal B cells license metabolic T-cell activation in NASH microbiota", antigen-independently and contribute to fibrosis by IgA-FcR signalling, 2023, pp.79, 296~313
131. Miyake T, "Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease", J Gastroenterol, 45, pp.859~867 (2010)
132. Morante-Palacios O, "Tolerogenic dendritic cells in autoimmunity and inflammatory diseases", Trends Immunol, 42, pp.59~75 (2021)
133. Sun L, "Dendritic cells and T cells, partners in atherogenesis and the translating road ahead", Front Immunol, 11, pp.1456~ (2020)
134. Huang C, "Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma : An emerging therapeutic strategy", Front Endocrinol(Lausanne), 14, pp.1145392~ (2023)
135. Lee JS, "Conventional dendritic cells impair recovery after myocardial infarction", J Immunol, 201, pp.1784~1798 (2018)
136. Deczkowska A, "XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis", Nat Med, 27, pp.1043~1054 (2021)
137. Deczkowska A, "Publisher correction : XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis", Nat Med, 28, pp.214~ (2022)
138. Heier EC, "Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis", J Hepatol, 66, pp.1241~1250 (2017)
139. Hao L, "Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining Akkermansia muciniphila in alcoholic steatohepatitis", Hepatology, 78, pp.896~910 (2023)
140. Chauhan KS, "IRF8 and BATF3 interaction enhances the cDC1 specific Pfkfb3 gene expression", Cell Immunol, 371, pp.104468~ (2022)
141. Goold HD, "Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors", J Immunol, 186, pp.4565~4572 (2011)
142. Murphy KM, "Effector T cell plasticity : flexibility in the face of changing circumstances", Nat Immunol, 11, pp.674~680 (2010)
143. Her Z, "CD4+ T cells mediate the development of liver fibrosis in high fat diet-induced NAFLD in humanized mice", Front Immunol, 11, pp.580968~ (2020)
144. Luo XY, "IFN-γ deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine-and choline-deficient high-fat diet", Am J Physiol Gastrointest Liver Physiol, 305, pp.G891~G899 (2013)
145. Jonsson AH, "Granzyme K+ CD8 T cells form a core population in inflamed human tissue", Sci Transl Med, 14, pp.eabo0686~ (2022)
146. Wen W, "Comprehensive analysis of NAFLD and the therapeutic target identified", Front Cell Dev Biol, 9, pp.704704~ (2021)
147. Zhang X, "CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis", J Hepatol, 61, pp.1365~1375 (2014)
148. Zhang X, "CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy", J Hepatol, 64, pp.160~170 (2016)
149. Van Herck MA, "The differential roles of T cells in non-alcoholic fatty liver disease and obesity", Front Immunol, 10, pp.82~ (2019)
150. Shimamura T, "Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model", J Immunol, 181, pp.4656~4665 (2008)
151. Gieseck RL 3rd, "Type 2 immunity in tissue repair and fibrosis", Nat Rev Immunol, 18, pp.62~76 (2018)
152. Kotsiou OS, "IL-33", ST2axis in organ fibrosis, 2018, pp.9, 2432~
153. Tan Z, "Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells", Cell Mol Immunol, 15, pp.388~398 (2018)
154. Miossec P, "Targeting IL-17 and TH17 cells in chronic inflammation", Nat Rev Drug Discov, 11, pp.763~776 (2012)
155. Moreno-Fernandez ME, "PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of nonalcoholic fatty liver disease", Cell Metab, 33, pp.1187~1204 (2021)
156. West EE, "Complement and the regulation of T cell responses", Annu Rev Immunol, 36, pp.309~338 (2018)
157. Taniki N, "Th17 cells in the liver : balancing autoimmunity and pathogen defense", Semin Immunopathol, 44, pp.509~526 (2022)
158. Gomes AL, "Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma", Cancer Cell, 30, pp.161~175 (2016)
159. Kaech SM, "Transcriptional control of effector and memory CD8+ T cell differentiation", Nat Rev Immunol, 12, pp.749~761 (2012)
160. Montacchiesi G, "Epigenetics and CD8+ T cell memory", Immunol Rev, 305, pp.77~89 (2022)
161. Wang B, "CXCR6 is required for antitumor efficacy of intratumoral CD8+T cell", J Immunother Cancer, 9, pp.e003100~ (2021)
162. Wolf MJ, "Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes", Cancer Cell, 26, pp.549~564 (2014)
163. Badovinac VP, "Viral infection results in massive CD8+ T cell expansion and mortality in vaccinated perforin-deficient mice", Immunity, 18, pp.463~474 (2003)
164. Gulzar N, "CD8+ T-cells : function and response to HIV infection", Curr HIV Res, 2, pp.23~37 (2004)
165. Terrell CE, "Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+)T cells and dendritic cells", Blood, 121, pp.5184~5191 (2013)
166. Boissonnas A, "Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes", Immunity, 32, pp.266~278 (2010)
167. Pfister D, "NASH limits anti-tumour surveillance in immunotherapy-treated HCC", Nature, 592, pp.450~456 (2021)
168. Wang H, "Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis", J Hepatol, 75, pp.1271~1283 (2021)
169. Zhou Y, "CD4+T cell activation and inflammation in NASH-related fibrosis", Front Immunol, 13, pp.967410~ (2022)
170. O’Leary K, "T cell drivers in NASH-HCC", Nat Rev Cancer, 21, pp.341~ (2021)
171. Maccioni L, "Duodenal CD8+ T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol-associated liver disease in humans", Aliment Pharmacol Ther, 56, pp.1055~1070 (2022)
172. Gu X, "New insights into iNKT cells and their roles in liver diseases", Front Immunol, 13, pp.1035950~ (2022)
173. Syn WK, "NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease", Gut, 61, pp.1323~1329 (2012)
174. Diao H, "Osteopontin as a mediator of NKT cell function in T cellmediated liver diseases", Immunity, 21, pp.539~550 (2004)
175. Kumar V, "NKT-cell subsets : promoters and protectors in inflammatory liver disease", J Hepatol, 59, pp.618~620 (2013)
176. Konduri V, "CD8+CD161+ T-cells : Cytotoxic memory cells with high therapeutic potential", Front Immunol, 11, pp.613204~ (2021)
177. Lee YJ, "Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells", Nat Immunol, 14, pp.1146~1154 (2013)
178. Li F, "Erratum : The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen", CD1d-dependent manner, 2017, pp.8, 15265~
179. Li F, "The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen", CD1d-dependent manner, 2017, pp.7, 13839~
180. Naimimohasses S, "Differential effects of dietary versus exercise intervention on intrahepatic MAIT cells and histological features of NAFLD", Nutrients, 14, pp.2198~ (2022)
181. Mabire M, "MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming", Nat Commun, 14, pp.1830~ (2023)
182. Wallace SJ, "Understanding the cellular interactome of non-alcoholic fatty liver disease", JHEP Rep, 4, pp.100524~ (2022)
183. Hegde P, "Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver", Nat Commun, 9, pp.2146~ (2018)
184. Semple JW, "Platelets and the immune continuum", Nat Rev Immunol, 11, pp.264~274 (2011)
185. Wong CH, "Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance", Nat Immunol, 14, pp.785~792 (2013)
186. Huo Y, "Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E", Nat Med, 9, pp.61~67 (2003)
187. Fujita K, "Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease", Gut, 57, pp.1583~1591 (2008)
188. Malehmir M, "Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer", Nat Med, 25, pp.641~655 (2019)
189. Jorch SK, "An emerging role for neutrophil extracellular traps in noninfectious disease", Nat Med, 23, pp.279~287 (2017)
190. Papayannopoulos V, "Neutrophil extracellular traps in immunity and disease", Nat Rev Immunol, 18, pp.134~147 (2018)
191. Gadd VL, "The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease", Hepatology, 59, pp.1393~1405 (2014)
192. Zang S, "Neutrophils play a crucial role in the early stage of nonalcoholic steatohepatitis via neutrophil elastase in mice", Cell Biochem Biophys, 73, pp.479~487 (2015)
193. van der Windt DJ, "Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis", Hepatology, 68, pp.1347~1360 (2018)
194. Guilliams M, "Liver macrophages in health and disease", Immunity, 55, pp.1515~1529 (2022)
195. Heymann F, "Immunology in the liver--from homeostasis to disease", Nat Rev Gastroenterol Hepatol, 13, pp.88~110 (2016)
196. Scott CL, "Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells", Nat Commun, 7, pp.10321~ (2016)
197. Krenkel O, "Liver macrophages in tissue homeostasis and disease", Nat Rev Immunol, 17, pp.306~321 (2017)
198. Krenkel O, "Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis", Gut, 69, pp.551~563 (2020)
199. Seidman JS, "Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis", Immunity, 52, pp.1057~1074 (2020)
200. Jaitin DA, "Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner", Cell, 178, pp.686~698 (2019)
201. Remmerie A, "Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver", Immunity, 53, pp.641~657 (2020)
202. Ramachandran P, "Resolving the fibrotic niche of human liver cirrhosis at single-cell level", Nature, 575, pp.512~518 (2019)
203. Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
204. Anstee QM, "From NASH to HCC : current concepts and future challenges", Nat Rev Gastroenterol Hepatol, 16, pp.411~428 (2019)
205. Shalapour S, "Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity", Nature, 551, pp.340~345 (2017)
206. Ma C, "NAFLD causes selective CD4(+)T lymphocyte loss and promotes hepatocarcinogenesis", Nature, 531, pp.253~257 (2016)
207. Ma HY, "IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease", J Hepatol, 72, pp.946~959 (2020)
208. Peiseler M, "Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits", J Hepatol, 77, pp.1136~1160 (2022)
209. Gawrieh S, "Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis", J Hepatol, 80, pp.684~693 (2024)
210. Sharma P, "Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival : an open label trial", J Hepatol, 50, pp.584~591 (2009)
211. Naranjo CA, "Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics", Clin Pharmacol Ther, 50, pp.96~106 (1991)
212. Zein CO, "Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis : new evidence on the potential therapeutic mechanism", Hepatology, 56, pp.1291~1299 (2012)
213. Baniasadi N, "Effects of pentoxifylline on non-alcoholic steatohepatitis : A randomized, double-blind, placebo-controlled trial in Iran", Hepat Mon, 15, pp.e32418~ (2015)
214. Ray S, "35kDa hyaluronan ameliorates ethanol driven loss of anti-microbial defense and intestinal barrier integrity in a TLR4-dependent manner", Matrix Biol, 115, pp.71~80 (2023)
215. Saikia P, "Hyaluronic acid 35 normalizes TLR4 signaling in Kupffer cells from ethanol-fed rats via regulation of microRNA291b and its target Tollip", Sci Rep, 7, pp.15671~ (2017)
216. Farrell GC, "NASH is an inflammatory disorder : Pathogenic, Prognostic and therapeutic implications", Gut Liver, 6, pp.149~171 (2012)
217. Nelson JE, "Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease : Possible role for MAPK and NF-κB?", Am J Gastroenterol, 111, pp.852~863 (2016)
218. Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
219. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT) : a multicentre, randomised, placebocontrolled trial", Lancet, 385, pp.956~965 (2015)
220. Ratziu V, "EDP-305 in patients with NASH : A phase II double-blind placebo-controlled dose-ranging study", J Hepatol, 76, pp.506~517 (2022)
221. Rotman Y, "Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease", Gut, 66, pp.180~190 (2017)
222. Thursz M, "Treatment of severe alcoholic hepatitis", Gastroenterology, 150, pp.1823~1834 (2016)
223. Lake-Bakaar G, "Glucocorticoids plus N-acetylcysteine in alcoholic hepatitis", N Engl J Med, 366, pp.476~477 (2012)
224. Tkachenko P, "Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis", Hepatol Int, 10, pp.983~987 (2016)
225. Lieber CS, "Alcoholic liver disease : new insights in pathogenesis lead to new treatments", J Hepatol, 32(1 Suppl), pp.113~128 (2000)
226. Xia SW, "Endoplasmic reticulum stress and protein degradation in chronic liver disease", Pharmacol Res, 161, pp.105218~ (2020)
227. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : Results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
228. Loomba R, "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis : A randomized, phase 2 trial", Hepatology, 67, pp.549~559 (2018)
229. Vogli S, "The effect of vitamin E supplementation on serum aminotransferases in non-alcoholic fatty liver disease(NAFLD) : A systematic review and meta-analysis", Nutrients, 15, pp.3733~ (2023)
230. Seo J, "Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice", Curr Res Food Sci, 8, pp.100663~ (2023)
231. Mueller M, "Ursodeoxycholic acid : Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients", Liver Int, 38, pp.523~531 (2018)
232. Moreau R, "G-CSF therapy for severe alcoholic hepatitis : targeting liver regeneration or neutrophil function?", Am J Gastroenterol, 109, pp.1424~1426 (2014)
233. Morgan TR, "Is granulocyte colony stimulating factor a new treatment for alcoholic hepatitis?", Clin Gastroenterol Hepatol, 16, pp.1564~1565 (2018)
234. Arab JP, "An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis", Hepatology, 72, pp.441~453 (2020)
235. Dong X, "Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA", J Adv Res, 55, pp.131~144 (2024)
236. Benedé-Ubieto R, "Breaking the barriers : the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease(MASLD)", Gut Microbes, 16, pp.2331460~ (2024)
237. Dubinkina VB, "Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease", Microbiome, 5, pp.141~ (2017)
238. Vatsalya V, "The beneficial effects of lactobacillus GG therapy on liver and drinking assessments in patients with moderate alcohol-associated hepatitis", Am J Gastroenterol, 118, pp.1457~1460 (2023)
239. Hong M, "Probiotics(Lactobacillus rhamnosus R0011 and acidophilus R0052)reduce the expression of toll-like receptor 4 in mice with alcoholic liver disease", PLoS One, 10, pp.e0117451~ (2015)
240. Bang CS, "Effects of Korean Red Ginseng(Panax ginseng), urushiol(Rhus vernicifera Stokes), and probiotics(Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052)on the gut-liver axis of alcoholic liver disease", J Ginseng Res, 38, pp.167~172 (2014)
241. Forrest E, "The role of prophylactic antibiotics for patients with severe alcohol-related hepatitis", JAMA, 329, pp.1552~1553 (2023)
242. Louvet A, "Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis : A randomized clinical trial", JAMA, 329, pp.1558~1566 (2023)
243. Jena PK, "Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model", Hepatobiliary Surg Nutr, 9, pp.170~182 (2020)
244. Alisi A, "Randomised clinical trial : The beneficial effects of VSL#3in obese children with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 39, pp.1276~1285 (2014)
245. Bomhof MR, "Histological improvement of non-alcoholic steatohepatitis with a prebiotic : a pilot clinical trial", Eur J Nutr, 58, pp.1735~1745 (2019)
246. Reimer RA, "Effect of chicory inulin-type fructancontaining snack bars on the human gut microbiota in low dietary fiber consumers in a randomized crossover trial", Am J Clin Nutr, 111, pp.1286~1296 (2020)
247. Wu WC, "Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats", World J Gastroenterol, 14, pp.313~317 (2008)
248. Cobbold JFL, "Rifaximin in non-alcoholic steatohepatitis : An open-label pilot study", Hepatol Res, 48, pp.69~77 (2018)
249. Shasthry SM, "Fecal microbiota transplantation in alcohol related liver diseases", Clin Mol Hepatol, 26, pp.294~301 (2020)
250. Bajaj JS, "A randomized clinical trial of fecal microbiota transplant for alcohol use disorder", Hepatology, 73, pp.1688~1700 (2021)
251. Pande A, "Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients : a randomized trial", Hepatol Int, 17, pp.249~261 (2023)
252. Xue L, "Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease : A randomized clinical trial", Front Cell Infect Microbiol, 12, pp.759306~ (2022)
253. Stols-Gonçalves D, "Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease : a multi-omics approach", Gut Microbes, 15, pp.2223330~ (2023)

관련 논문AI추천